Public Health Monitoring of Pregnancy-Related Thrombotic Risk

Abstract

Pregnancy significantly increases the risk of thrombotic events, posing unique challenges for maternal health. This review critically examines the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, and management of pregnancy-related thrombotic risk, with an emphasis on public health monitoring. Drawing from recent evidence and guideline-based recommendations, we explore emerging therapies, preventive strategies, and the necessity for robust surveillance systems to optimize maternal outcomes. The article aims to provide clinicians and healthcare professionals with a comprehensive, practical, and up-to-date resource for improving the detection, prevention, and management of thrombosis during pregnancy.

Introduction

Venous thromboembolism (VTE), encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a leading cause of maternal morbidity and mortality globally. The physiological changes of pregnancy, compounded by genetic and acquired risk factors, create a hypercoagulable state that elevates thrombotic risk. As maternal health outcomes are closely linked to the timely recognition and management of these complications, public health monitoring has become essential. This article reviews the scientific and clinical landscape of pregnancy-related thrombotic risk, providing evidence-based insights for healthcare providers.

Epidemiology / Disease Burden

Globally, the estimated incidence of VTE during pregnancy and the postpartum period ranges from 1 to 2 per 1,000 pregnancies. PE accounts for 10–15% of maternal deaths in developed countries and is a significant contributor to maternal morbidity in low-resource settings. Epidemiological data reveal that the risk of VTE is four to five times higher in pregnant women than in non-pregnant women of similar age. Importantly, the risk persists postpartum, with the highest incidence occurring in the first six weeks after delivery. Surveillance data underline the need for systematic public health monitoring to identify at-risk populations and implement timely interventions.

Pathophysiology

The pathogenesis of pregnancy-related thrombosis is multifactorial and centers on Virchow's triad: venous stasis, endothelial injury, and hypercoagulability. Anatomically, the gravid uterus exerts pressure on pelvic veins, impeding venous return, particularly in the left lower extremity. Hormonal changes, notably increased progesterone and estrogen, promote venous dilation and stasis. Enhanced levels of clotting factors (fibrinogen, factors VII, VIII, IX, X, and XII) and decreased fibrinolytic activity further shift the hemostatic balance toward thrombosis. Placental-derived microparticles and reduced levels of protein S add to the prothrombotic milieu. These physiological adaptations, while protective against hemorrhage, inadvertently increase thrombotic risk.

Risk Factors

Several maternal, obstetric, and medical risk factors modulate the propensity for thrombotic events during pregnancy. Key maternal factors include advanced maternal age, obesity (BMI >30), multiparity, and smoking. Obstetric contributors encompass cesarean delivery especially emergency procedures, prolonged immobilization, preeclampsia, multiple gestation, and assisted reproductive technologies. Underlying thrombophilias hereditary (e.g., Factor V Leiden, prothrombin G20210A mutation, antithrombin, protein C or S deficiency) and acquired (e.g., antiphospholipid syndrome) significantly amplify risk. Recent infection, dehydration, and personal or family history of VTE are additional modifiers. Accurate risk stratification is essential for individualized preventive strategies.

Clinical Features

The clinical presentation of VTE in pregnancy is often subtle and overlaps with common pregnancy symptoms, complicating timely diagnosis. DVT typically manifests as unilateral leg pain, swelling, erythema, and tenderness, more frequently affecting the left leg due to anatomical predisposition. PE may present with acute-onset dyspnea, chest pain, tachycardia, or syncope. Non-specificity of these symptoms necessitates a high index of suspicion, especially in women with known risk factors. Pregnancy-adapted clinical prediction rules and prompt evaluation are critical to minimize diagnostic delays and subsequent morbidity.

Diagnosis

Diagnostic evaluation must balance maternal and fetal safety, minimizing radiation exposure while ensuring accuracy. Compression ultrasonography is the first-line modality for suspected DVT, offering high sensitivity and specificity without ionizing radiation. For suspected PE, ventilation-perfusion (V/Q) scanning or computed tomography pulmonary angiography (CTPA) are considered. V/Q scanning is preferred in women with normal chest X-ray due to lower fetal radiation dose, while CTPA is favored in those with abnormal chest imaging or equivocal V/Q results. D-dimer levels are physiologically elevated in pregnancy, limiting their diagnostic utility. Clinical algorithms and multidisciplinary assessment guide appropriate imaging selection.

Treatment & Management

Low molecular weight heparin (LMWH) is the anticoagulant of choice for managing pregnancy-related VTE, owing to its safety profile and lack of placental transfer. Dosage is weight-adjusted, and anti-Xa monitoring may be necessary in specific scenarios (e.g., renal impairment, obesity). Unfractionated heparin is reserved for cases where rapid reversal may be needed, such as imminent delivery. Warfarin and direct oral anticoagulants are contraindicated owing to teratogenicity and limited safety data, respectively. Anticoagulation is typically continued for at least six weeks postpartum, with a minimum total duration of three months. Multidisciplinary care including hematology, obstetrics, and anesthesiology optimizes maternal and fetal outcomes.

Recent Advances / Emerging Therapies

Recent research is focused on refining risk prediction models, developing individualized prophylaxis protocols, and investigating novel anticoagulants. Advances in genetic screening for thrombophilias and point-of-care diagnostic tools enhance early detection. Extended postpartum prophylaxis is being evaluated in women with persistent risk factors. The role of mechanical prophylaxis, such as graduated compression stockings and intermittent pneumatic compression, is also under investigation. Emerging data on the safety of DOACs in breastfeeding women may expand future therapeutic options. Public health initiatives leveraging electronic health records for real-time surveillance and risk stratification are demonstrating promise in reducing maternal morbidity rates.

Guideline Recommendations

Professional societies, including the American College of Obstetricians and Gynecologists (ACOG), Royal College of Obstetricians and Gynaecologists (RCOG), and American Society of Hematology (ASH), provide clear guidance on risk assessment, prophylaxis, and management. Universal risk assessment at the first prenatal visit and postpartum is emphasized. Pharmacologic prophylaxis is recommended for high-risk women, particularly those with prior VTE or significant thrombophilia, while mechanical prophylaxis is reserved for those with contraindications to anticoagulation. Guidelines advocate for patient education, multidisciplinary management, and ongoing public health surveillance to optimize outcomes.

Conclusion

Pregnancy-related thrombotic risk remains a significant public health challenge, necessitating ongoing vigilance and evidence-based management. Understanding the complex interplay of physiological, genetic, and environmental factors is key to improving maternal outcomes. Advances in risk stratification, diagnostics, and therapeutics, coupled with robust surveillance systems, offer the potential to reduce the burden of VTE in pregnancy. Continued research, guideline refinement, and clinician education are essential to ensure safe and effective care for this vulnerable population.